Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer
17 August 2021 - 6:05AM
Business Wire
- Former Vice President and Global HR Head of
Oncology and Pharma Development at Novartis brings extensive
leadership experience focused on talent, culture, and diversity
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical
company focused on the treatment of serious diseases in which
protein growth factors play a fundamental role, today announced the
appointment of Caryn Parlavecchio as Chief Human Resources Officer.
She will join the executive team, bringing more than 20 years of
experience as a senior leader and strategic executive in the
biotechnology and pharmaceutical industries.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210816005424/en/
Caryn Parlavecchio, Chief Human Resources
Officer at Scholar Rock (Photo: Business Wire)
“Caryn’s substantial industry knowledge and extensive leadership
experience developing and implementing HR strategies, talent
acquisition, and diversity and inclusion will be critical in
guiding Scholar Rock’s accelerated growth plans,” said Nagesh
Mahanthappa, Ph.D. Interim CEO of Scholar Rock. “We are honored to
have Caryn join the team to grow our company and expand our
capabilities during this important juncture as we advance towards
late-stage development and begin to plan for commercialization for
patients in need.”
“I am excited to join Scholar Rock and be a part of this
talented and fast-growing team that is dedicated to moving our
programs forward to address unmet medical needs,” said
Parlavecchio. “I have been inspired by the Company’s progress and
have seen the enormous potential of our clinical programs and
scientific platform. I look forward to supporting Scholar Rock’s
future by attracting and developing top talent at all stages, from
research through commercialization, serving our teams and creating
a meaningful and inclusive work experience for all of our
employees.”
Ms. Parlavecchio most recently served as Vice President and
Chief Human Resources Officer at Holy Name Medical, an acute care
facility, for the past year, during which she was a member of the
executive team, HR committee, finance committee, and compensation
and benefits committees. Prior to, she held various human resource
leadership positions during her nearly 20-year tenure at Novartis
Pharmaceuticals, including Vice President and Global HR Head,
Oncology and Pharma Development, Vice President and Country HR
Head, and Vice President, Human Resources Services, North America.
Ms. Parlavecchio holds a Master of Arts in Counseling Psychology
and a Bachelor of Arts in English, both from Seton Hall
University.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative medicines
for the treatment of serious diseases in which signaling by protein
growth factors plays a fundamental role. Scholar Rock is creating a
pipeline of novel product candidates with the potential to
transform the lives of patients suffering from a wide range of
serious diseases, including neuromuscular disorders, cancer,
fibrosis and anemia. Scholar Rock’s approach to targeting the
molecular mechanisms of growth factor activation enabled it to
develop a proprietary platform for the discovery and development of
monoclonal antibodies that locally and selectively target these
signaling proteins at the cellular level. By developing product
candidates that act in the disease microenvironment, the Company
intends to avoid the historical challenges associated with
inhibiting growth factors for therapeutic effect. Scholar Rock
believes its focus on biologically validated growth factors may
facilitate a more efficient development path. For more information,
please visit www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
ability of new executives to influence Scholar Rock’s progress,
Scholar Rock’s ability to develop its pipeline, and Scholar Rock’s
growth expectations. The use of words such as “may,” “might,”
“will,” “should,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “project,” “intend,” “future,” “potential,” or
“continue,” and other similar expressions are intended to identify
such forward-looking statements. All such forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include Scholar Rock’s ability to
provide the financial support, resources and expertise necessary to
identify and develop product candidates on the expected timeline,
the data generated from Scholar Rock’s nonclinical and preclinical
studies and clinical trials and the impacts of public health
pandemics such as COVID-19 on business operations and expectations,
as well as those risks more fully discussed in the section entitled
"Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2021, as well as discussions of
potential risks, uncertainties, and other important factors in
Scholar Rock’s subsequent filings with the Securities and Exchange
Commission. Any forward-looking statements represent Scholar Rock’s
views only as of today and should not be relied upon as
representing its views as of any subsequent date. All information
in this press release is as of the date of the release, and Scholar
Rock undertakes no duty to update this information unless required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210816005424/en/
Scholar Rock Contacts: Investor Contact: Catherine
Hu chu@scholarrock.com Media Contact: Ariane Lovell Finn
Partners ariane.lovell@finnpartners.com 917-565-2204
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024